Lasa Supergenerics Limited has informed the Exchange regarding Change in Director(s) of the company.
LASA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lasa Supergenerics Limited has appointed four new Additional Directors as Non-Executive Independent Directors in a board meeting held on August 5, 2025. The appointees are Mr. Ketan Bhau Songal, Mr. Pravin Gadalya Lachake, Mr. Yogesh Hari Ughada, and Mrs. Rekha Hemant Wakh (Woman Director). Each has been appointed for a 5-year term until August 4, 2031, subject to shareholder approval. All four are Indian nationals, hold no shares in the company, have NIL directorships in other public companies, and are not debarred by SEBI from holding director positions. Notably, the appointees' listed expertise lies in veterinary sciences, animal nutrition, and poultry operations rather than the pharmaceutical/supergenerics sector the company operates in.
The bulk induction of four independent directors at once could strengthen board composition and gender diversity (with one woman director), but shareholders may question their relevance to the pharma business given their backgrounds and the fact that all four are relatively young (aged 22-28) with no prior listed-company board experience. Watch for the shareholder approval outcome via postal ballot or general meeting.